Patents by Inventor Stefan Barghorn

Stefan Barghorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
    Publication number: 20240075114
    Abstract: The invention relates to immunogenic products based on mutein amyloid ? (A?) amino acid sequences, in particular to oligomers of A? muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.
    Type: Application
    Filed: October 27, 2022
    Publication date: March 7, 2024
    Inventors: Stefan Barghorn, Simone Giaisi, Heinz Hillen, Andreas Striebinger
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20220017607
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: February 22, 2021
    Publication date: January 20, 2022
    Applicants: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
  • RGMa Fragment Based Diagnostic Assay
    Publication number: 20220018855
    Abstract: Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases.
    Type: Application
    Filed: March 2, 2021
    Publication date: January 20, 2022
    Inventors: Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
  • RGMa Fragment Based Diagnostic Assay
    Publication number: 20200241012
    Abstract: Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases.
    Type: Application
    Filed: September 4, 2019
    Publication date: July 30, 2020
    Inventors: Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
  • Anti-A? globulomer 4D10 antibodies
    Patent number: 10538581
    Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: January 21, 2020
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
  • Monoclonal antibodies against amyloid beta protein and uses thereof
    Patent number: 10323084
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: June 18, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller
  • Monoclonal antibodies against amyloid beta protein and uses thereof
    Patent number: 10208109
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: February 19, 2019
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO KG
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas R. Striebinger, Patrick Keller
  • Amyloid-beta binding proteins
    Patent number: 10047121
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to ??(20-42) globulomer or any ?? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: August 14, 2018
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Chung-Ming Hsieh
  • A? conformer selective anti-A? globulomer monoclonal antibodies
    Patent number: 9951125
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: April 24, 2018
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
  • AMYLOID-BETA BINDING PROTEINS
    Publication number: 20180094049
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Application
    Filed: October 17, 2017
    Publication date: April 5, 2018
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20180066044
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: July 27, 2017
    Publication date: March 8, 2018
    Inventors: Heinz HILLEN, Stefan BARGHORN, Boris LABKOVSKY, Ulrich EBERT, Andreas STRIEBINGER, Patrick KELLER
  • Amyloid-beta binding proteins
    Patent number: 9822171
    Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: November 21, 2017
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giaisi, Ulrich Ebert, Lorenzo Benatuil
  • ANTI-Aß GLOBULOMER 4D10 ANTIBODIES
    Publication number: 20170022269
    Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
    Type: Application
    Filed: October 11, 2016
    Publication date: January 26, 2017
    Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
  • Anti-A? globulomer 7C6 antibodies
    Patent number: 9540432
    Abstract: Anti-A? globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies. The present invention relates to anti-A? globulomer antibodies having a binding affinity to A?(20-42) globulomer that is greater than the binding affinity of the antibody to A?(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors, methods of producing said antibodies, compositions comprising said antibodies, therapeutic and diagnostic uses of said antibodies and corresponding methods relating to Alzheimer's disease and other amyloidoses.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: January 10, 2017
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG, ABBVIE INC.
    Inventors: Stefan Barghorn, Heinz Hillen, Boris Labkovsky, Andreas R. Striebinger, Patrick Keller, Ulrich Ebert
  • Abeta CONFORMER SELECTIVE ANTI-Abeta GLOBULOMER MONOCLONAL ANTIBODIES
    Publication number: 20160326238
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Application
    Filed: May 16, 2016
    Publication date: November 10, 2016
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
  • A? conformer selective anti-A? globulomer monoclonal antibodies
    Patent number: 9394360
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: July 19, 2016
    Assignees: ABBVIE INC., ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
  • MONOCLONAL ANTIBODIES AGAINST AMYLOID BETA PROTEIN AND USES THEREOF
    Publication number: 20160159891
    Abstract: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 9, 2016
    Inventors: Heinz Hillen, Stefan Barghorn, Boris Labkovsky, Ulrich Ebert, Andreas Striebinger, Patrick Keller
  • Abeta conformer selective anti-Abeta globulomer monoclonal antibodies
    Patent number: 9359430
    Abstract: The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: June 7, 2016
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Stefan Barghorn, Heinz Hillen, Andreas R. Striebinger, Boris Labkovsky, Ulrich Ebert, Patrick Keller
  • RGMa Fragment Based Diagnostic Assay
    Publication number: 20160069907
    Abstract: Provided are diagnostic assays and method s of using the diagnostic assays for detecting and quantifying RGMa fragments in a sample. The methods may be used detection of the RGMa fragments to monitoring drug treatment and effectiveness of drug treatment in neurodegenerative diseases.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Inventors: Stefan Barghorn, Bernhard Klaus Mueller, Martin Schmidt, Andreas Striebinger
  • IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID beta (Abeta) AMINO ACID SEQUENCES AND USES THEREOF
    Publication number: 20160000891
    Abstract: The invention relates to immunogenic products based on mutein amyloid ? (A?) amino acid sequences, in particular to oligomers of A? muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 7, 2016
    Inventors: Stefan Barghorn, Simone Giaisi, Heinz Hillen, Andreas Striebinger